Cemiplimab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Cemiplimab
Monoclonal antibody
Type Whole antibody
Source Human
Target PD-1
Clinical data
Synonyms REGN-2810
ATC code
  • None
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6380H9808N1688O2000S44
Molar mass 143.6 g/mol

Cemiplimab (REGN-2810) is a monoclonal antibody under development as a drug for the treatment of squamous cell skin cancer,[1] myeloma,[2] and lung cancer.[3]

References[edit]

  1. ^ H. Spreitzer (2 January 2018). "Neue Wirkstoffe: Cemiplimab". Österreichische Apothekerzeitung (in German) (1/2018). 
  2. ^ Clinical trial number NCT03194867 for "Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT03430063 for "A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer" at ClinicalTrials.gov